Spots Global Cancer Trial Database for A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
Official Title: A Phase I/II Clinical Study of Avapritinib in Chinese Subjects With Unresectable or Metastatic Gastrointestinal Stromal Tumor
Study ID: NCT04254939
Conditions
Interventions
Study Description
Brief Summary: This study is an open-label, multicenter, phase I/II study to evaluate the safety, PK and clinical efficacy of avapritinib in Chinese subjects with unresectable or metastatic GIST. The study consists of two parts: dose escalation (phase I) and dose expansion (phase II).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Cancer Hospital, Beijing, Beijing, China
Chinese PLA General Hospital, Beijing, Beijing, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
The First Affiliated Hospital of Nanchang Medical University, Nanchang, Jiangxi, China
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Fudan University Zhongshan Hospital (General Surgery Department), Shanghai, Shanghai, China
Fudan University Zhongshan Hospital (Internal Tumor Department), Shanghai, Shanghai, China
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Xinjiang Medical University Cancer Hospital, Urumqi, Xinjiang, China
The First Affiliated Hospital Zhe Jiang University, Hangzhou, Zhejiang, China
Contact Details
Name: Lin SHEN, MD
Affiliation: Peking University Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
